To evaluate the association between hypertension, male erectile function, Rho-kinase, and cyclic GMP pathways, we monitored neurogenic erectile response in spontaneously hypertensive (SHR) vs normotensive rats. We also evaluated SHR erectile function before and after intracavernosal injection of either the specific Rho-kinase inhibitor Y-27632 or a combination of Y-27632 and the PDE5 inhibitor zaprinast to prevent cGMP degradation. SHR had lower resting baseline corpus cavernosum pressure and a higher threshold for development of tumescence than normotensive rats. In SHR, Y-27632 administration reversed hypertension-related changes in male erectile function; Rho-kinase antagonism and PDE5 inhibition in combination had a synergistic effect in improving the neurogenic erectile response. Our data indicate that hypertension is associated with impairment in the SHR neurogenic erectile response that may involve a derangement in hemodynamic mechanisms in penile erectile tissue. Rho-kinase inhibition alone or combined with PDE5 inhibition may be of value in treating hypertension-related ED.
Introduction
Hypertension is a well-recognized risk factor for male sexual impotence. [1] [2] [3] Endothelial dysfunction, hormonal abnormalities, and vascular factors are considered possible etiologic factors. 2 Clinical studies suggest that antihypertensive drugs per se could affect the compliance of the erectile tissue. 3, 4 Normal erectile function is characterized by a delicate in vivo balance between the effects of vasoconstricting and vasorelaxing neurotransmitters/hormones on the level of corporal smooth muscle tone. 5 It is believed that some threshold amount of smooth muscle relaxation must occur in order to convert a tonically contracted, flaccid penis to the fully erect state with sufficient rigidity to permit intercourse. Nitric oxide (NO), a gaseous molecule generated by nonadrenergic, noncholinergic nerve endings, has been recognized as playing a key role in mediating penile smooth muscle relaxation to initiate an erectile response in animals and humans. 6 NO is known to stimulate soluble guanylate cyclase and generate cGMP to produce cavernosal smooth muscle relaxation. 6 It is also known that the cGMP synthetic pathway and soluble guanylyl cyclase (sGC) in particular can be significantly impaired in hypertension. [7] [8] [9] The physiological relevance of this cGMP pathway is evidenced by the successful therapeutic use of cGMP phosphodiesterase inhibitors (PDE5) such as sildenafil (Viagra) in the treatment of erectile dysfunction (ED). 10 The contracted (flaccid) state of the cavernosal smooth muscle is believed to be mediated by release of norepinephrine, endothelin-1, neuropeptide Y, prostanoids, and angiotensin II. 11 Besides the wellestablished nonadrenergic contraction mechanisms in the penis, an additional mechanism involving increased sensitivity to ionic calcium has recently been proposed. 12, 13 This pathway involves RhoA, a small monomeric G-protein that activates Rhokinase. Activated Rho-kinase phosphorylates the regulatory subunit of smooth muscle myosin phosphatase (SMPP-IM). Inhibitory phosphorylation of SMPP-IM leads to sensitization of myofilaments to Ca 2 þ . 14 A specific inhibitor of Rho-kinase, ( þ )-(R)-transB (1-amino-ethyl-N-(4-pyridyl) cyclohexacar-boxamide dihydrochloride monohydrate (Y-27632), has been shown to lower blood pressure in hypertensive but not in normotensive rats, suggesting that it has vasorelaxant activity preferentially on vascular beds with high basal tone. 15 Intracavernosal injection of Y-27632 in rats has been shown to induce penile erection that was initially thought to act independently of the NO-cGMP pathway. 12 However, recent studies suggest a possible interplay between the NO-cGMP and Rho-kinase pathways. [16] [17] [18] Recently, exogenous NO administration has been shown to inhibit RhoA-mediated vasoconstriction and produce an erectile response in rats. 16 In spontaneously hypertensive rats (SHR), hypertension was associated with significant structural alterations in the penile vasculature similar to those in other vascular beds. An elevated penile cavernosal vasoconstrictive tone is believed to play a role in these altered penile hemodynamic mechanisms. 19 If the critical level of relaxation is impaired, there will be incomplete resistance to the outflow of blood from the corpora, and a spectrum of penile tumescence will result, ranging from flaccidity to near but not complete erection. Although it is commonly assumed that hypertension somehow predisposes men to impotence, the precise mechanism is not clearly understood.
The involvement of Rho-kinase in hypertension-related vascular disorders has been well documented. [20] [21] [22] Due to the association of abnormal cavernosal smooth muscle tone with hypertension-related ED, we hypothesized that upregulated Rho-kinase activity in the penile vasculature could be an underlying mechanism in hypertensionrelated ED. In addition, impairment in NO-cGMPmediated smooth muscle relaxation mechanisms could further exacerbate penile hemodynamic processes. In the current study, we evaluated the correlation between hypertension and erectile function in a genetically hypertensive (SHR) rat model. We included a corresponding age group of normotensive control animals of the Wistar-Kyoto (WKY) strain to assess the impact of hypertension on these parameters. We also examined the hypotheses that antagonism of upregulated Rho-kinase activity could reverse the hypertension-related changes in male erectile function, and that a combination of Rho-kinase antagonism and PDE5 inhibition may have a synergistic effect in improving the erectile response in hypertensive animals.
Materials and methods

Animals and experimental design
Male adult (300-350 g) SHR (n ¼ 16) were employed as a model for hypertension. An age-matched control population of normotensive WKY rats (n ¼ 16) was used for comparison. Animals were maintained on a 12 h light and dark cycle with food and water available ad libitum, and this study protocol was approved by the Institutional Animal Care and Use Committee. The rats were anesthetized using an intraperitoneal injection of a mixture of ketamine (97 mg/kg) and xylazine (13 mg/kg); an adequate level of anesthesia was maintained by supplemental doses of ketamine. Arterial blood pressure (AP) was monitored by cannulating the carotid artery with Intramedic PE 50 tubing (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) connected to a pressure transducer. Corpus cavernosum pressures (CCP) were recorded by cannulating either of the corporal bodies approximately 3-5 mm above the base of the penis. This cannulation was performed using a 25-gauge IV butterfly needle filled with 100 U/ml heparinized saline (Vacutainer, Becton, Dickinson and Company, Franklin Lakes, NJ, USA), which was also connected to a pressure transducer. Pressures were measured using two UFI pressure transducers (UFI, Morro Bay, CA, USA) in series with a UFI amplifier. The data were acquired by connecting the amplifier to a PC running Labview (National Instruments Corporation, Austin, TX, USA).
The major pelvic ganglion (MPG) was identified by dissecting the fibrous capsule posterior to the intersection of the lateral lobes of the prostate and the vas deferens with cotton tips. The MPG was then subjected to electrical field stimulation (EFS) with a voltage via two platinum electrodes delivered from a Grass S48 stimulator (Grass-Telefactor, West Warwick, RI, USA). 15 Stimulus levels of 1.5, 3, and 4.5 V were used for durations of 1 min each; the rats were given a 5-min rest period between stimulations. CCP levels during stimulation were recorded directly into a computerized data acquisition program. Mean arterial pressure (MAP) was calculated by numerically integrating the pressure waveform in the carotid using the following relation: MAP ¼ ð1=TÞ
PðtÞ dt, where the period of the waveform is T seconds. An executable developed under MATLAB was used to calculate MAP from the discrete data. We employed three protocols to test our hypotheses.
The impact of hypertension as well as the correlation of blood pressure to EFS-induced erectile response was evaluated in SHR and WKY rats by stimulating the MPG at 1.5, 3.0, and 4.5 V and recording AP and CCP as described above.
Protocol 2 (n ¼ 16): To test the hypothesis that elevated penile RhoA levels contribute to hypertension-related changes in erectile response and that the specific Rho-kinase antagonist Y-27632 (Calbiochem, San Diego, CA, USA) reverses these changes in male erectile function, 16 SHR animals were Hypertension and erectile dysfunction N Wilkes et al subjected to Protocol 1 followed by the intracavernosal administration of Y-27632 (50 nmol in 5 ml of saline). After 10-15 min, Protocol 1 was repeated. Penile tissues from both SHR and WKY rats were harvested and subjected to the evaluation of RhoA protein expression. Protocol 3 (n ¼ 16): To test the hypothesis that a combination of Rho-kinase antagonism and PDE5 inhibition may have a synergistic effect in improving the erectile response in hypertensive animals, the SHR animals were subjected to Protocol 1 and then to the intracavernosal administration of the PDE5 inhibitor zaprinast (ZAP; Sigma Chemicals, St Louis, MO, USA) (100 mg in 5 ml of saline) followed by Y-27632 (50 nmol in 5 ml of saline). After 10-15 min, Protocol 1 was repeated.
All drug solutions were stored in a freezer in amber bottles; working solutions were prepared on a frequent basis and kept cold until injection time. In both SHR and WKY animals, the drugs were administered intracavernosally in small volumes (5 ml) when CCP was at a baseline value. The effect of a single injection agent on CCP was measured until CCP returned to the preinjection level. The next injection was made at least 10-15 min after CCP had returned to a stable baseline. An injection of 5 ml of saline vehicle had no significant sustained effect on CCP.
Extraction of Rho protein from rat penile tissue
Penile tissue (corpora cavernosa) from SHR and WKY rats was harvested, washed in phosphate-buffered saline (PBS), and then individually homogenized in an excess of homogenization cocktail (50 mM TrisHCl, 1% NP-40, 0.25% deoxycholate, 0.15 M NaCl, 1 mM EDTA, 1 mM PMSF, and 1 mg/ml each of the following protease inhibitors: aprotinin, leupeptin, pepstatin, and NaF) (Sigma Chemical Corp., St Louis, MO, USA). The homogenized material was then centrifuged at 10 000 rpm and the concentration of extracted proteins in the supernatant was determined using the BCA Protein Assay reagent. 23 
Western blot analysis of cavernosal RhoA expression
Equal amounts of protein (25 mg) were loaded onto a 12% polyacrylamide gel (29:1) along with a prestained molecular weight standard (Kaleidoscope markers, range 200-7.5 kDa, Bio Rad, Hercules, CA, USA). After overnight transfer to nitrocellulose membrane (Protran 0.45 mm pore size, S & S, Keene, NH, USA) in 25 mM Tris-192 mM glycine-20% methanol transfer buffer, the nonspecific binding sites were blocked with 5% milk in PBS, pH 7.5 (PBS). The membrane was then incubated overnight with primary rabbit antibody for RhoA (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA; 1:1000 dilution).
This polyclonal antibody recognizes the p21 internal domain of RhoA with immunostained bands having a molecular weight of 24 kDa. After washing in PBS, the blots were incubated with anti-rabbit-horseradish peroxidase secondary antibody (Sigma Chemical Co, St Louis, MO, USA; 1:50 000 dilution) for 30 min followed by another washing and then a 5-min incubation in supersignal chemiluminescent substrate (SuperSignal West Pico; Pierce, Rockford, IL, USA). The signal was detected on X-Omat AR film and processed in an automatic film developer. Protein bands were quantified using an image analysis program (Scion Image, Scion Corporation, Frederick, MD, USA) and the intensities normalized to the amount of protein in the supernatant. 23 
Statistical analysis
Analysis of the data presented in Figures 2-4 was performed using a repeated-measures ANOVA. Significant differences between groups were determined by using a two-tailed unpaired t-test assuming unequal variances with the Bonferroni correction for repeated comparisons of groups. Specifically significant differences between the individual SHR, SHR þ Y-27632, and SHR þ Y-27632 þ ZAP groups were determined using the corrected unpaired two-tailed t-test. The differences between the WKY and SHR Western blot results were analyzed with an uncorrected unpaired twotailed Student's t-test. A P-value of less than 0.05 was considered significant.
Results
Comparison of EFS-induced erectile response in SHR and WKY rats
We selected voltages of 1.5, 3, and 4.5 V for the present evaluations based on our preliminary experiments in SHR species. Voltages lower than 1.5 V failed to produce a consistent response in SHR. During resting periods (in the absence of stimulation), the baseline CCP remained stable throughout the experiment. The CCP and CCP/MAP data are summarized in Table 1 between the groups at all stimulation levels ( Figure  2a and b) . The SHR group exhibited a 30-35% lower CCP response when compared to WKY rats. A similar trend was observed for the CCP/MAP index. At 1.5 V, the difference in CCP/MAP between the SHR and WKY groups was 41%. The differences in the CCP/MAP ratio were more pronounced between the groups at the 3 and 4.5 V stimulation levels. At 3 and 4.5 V, the differences between the two groups were 56 and 61% respectively (Po0.01) (Figure 2b ).
Efficacy of Rho-kinase and PDE5 inhibition on EFSinduced erectile response in hypertensive rats
The effect of Rho-kinase inhibition on EFS-induced erectile response in SHR as measured by changes in CCP is illustrated in Figure 3a and b. In SHR, the impact of Rho-kinase inhibition following intracavernosal Y-27632 could be seen immediately.
A significant improvement in erectile response was observed at all voltage levels of stimulation (Figure 3a) . In Y-27632-injected SHR, at 1. (Figure 3b) .
A combination of Rho-kinase inhibition with Y-27632 and PDE5 inhibition with zaprinast resulted in a synergistic improvement in neurogenic erectile response in SHR (Figure 4a and b) . Representative tracings of CCP changes are shown in Figure 5 . This combination produced a consistent 20-28% improvement in erectile response when compared to the Rho-kinase inhibition alone (Figure 4a and b) . The improvement was taken as the mean peak CCP during EFS after administration of Y-27632 and zaprinast as compared to the same parameter after injection of Y-27632 alone. The mean increase in CCP and the index of CCP/MAP were significant at all levels of stimulation (Po0.05), suggesting a maximal relaxation with a combination of the RhoA/Rho-kinase and PDE5 inhibition.
Evaluation of systemic arterial pressure changes
MAP in SHR ranged from 150 to 200 mmHg, whereas WKY rats had a MAP range of 80-120 mmHg. Changes in MAP following MPG stimulation are illustrated in Figure 7a . There was a voltage-dependent decrease in MAP in both groups of animals; however, there was no significant difference in these changes between the groups at any voltage (Figure 7a) . Intracavernosal injection of Y-27362 and zaprinast resulted in a marginal 10-35 mmHg drop in MAP in SHR (not significant; Figure 7b ).
Western blot analysis
To assess differences in RhoA signaling pathways in corporal tissues harvested from SHR and WKY rats, Hypertension and erectile dysfunction N Wilkes et al protein was extracted and subjected to Western blot analysis. Our results revealed the endogenous expression of RhoA proteins (corresponded to a band in 24 kDa range) in SHR as well as WKY rats (Figure 6a ). Image analysis of immunoblots demonstrated a 53% increase in the expression of RhoA in penile tissues from SHR species compared to that of WKY rats (Po0.05; Figure 6b ).
Discussion
In the present study, we have demonstrated that there is a significant impairment in erectile function in an experimental animal model of hypertension (SHR). We have found that (1) there are differences in resting baseline as well as EFS-induced increases in CCP between SHR and WKY rats, (2) increased penile expression of Rho-A protein, (3) improvement of EFS-induced erectile response after RhoARho-kinase inhibition, and (4) synergistic potentiation of erectile response following RhoA-Rho-kinase inhibition and PDE5 antagonism in SHR species. The impact of hypertension on male sexual function has been the focus of several clinical previous investigations. 2, 3, 24 Animal behavioral studies employing the well-recognized genetic model (SHR) of hypertension have demonstrated a significant impairment of erectile reflexes in hypertensive animals. 25 Hemodynamic studies in SHR species have shown that hypertension in these animals leads to structural changes in penile vasculature similar to those in other vascular beds, characterized by a narrow vascular lumen and increased medial smooth muscle bulk. 26 In addition, these studies imply the loss of functional control mechanisms that protect the penile vasculature from structural changes that may have a negative impact on penile blood flow. 26 Recent in vivo physiological studies in experimental animal models described impairment of erectile response in hypertensive animals. Chitaley et al 27 demonstrated a decrement in erectile response in stroke-prone SHR animals. Behr-Roussel et al 28 using an SHR animal model demonstrated impairment of erectile response and attributed this to hypertension-related dysfunctional a-adrenergic contraction mechanisms and elevated cyclooxygenase constrictor tone in these animals. Overall, these animal studies suggest that there is elevated constrictor tone in the SHR penile tissues leading to impairment in penile perfusion and associated erectile mechanisms in the SHR species.
Penile smooth muscle contractile tone is believed to be mediated by release of norepinephrine, endothelin-1, neuropeptide Y, prostanoids, and angiotensin II. 11 Besides these well-established mechanisms in the penis, an additional mechanism involving increased sensitivity to ionic calcium has recently been proposed. 12 This RhoA signaling pathway, through activation of Rho-kinase leading to inhibition of myosin phosphatase resulting in an increase in myosin light chain (MLC) phosphorylation and force in smooth muscle, has been recognized to play a significant role in several vascular disorders. 29, 30 The involvement of Rho-kinase in hypertension was first indicated by Uehata et al 15 in rat models of hypertension. In vivo administration of Y-27632, a specific inhibitor of Rho-kinase, preferentially lowered hypertension in these animal Hypertension and erectile dysfunction N Wilkes et al models. 15, 30 In addition to the findings of these animal studies, the involvement of Rho-kinase in the pathogenesis of human hypertension has also been recently established. Intra-arterial infusion of fasudil in hypertensive patients decreased the peripheral vascular resistance in these patients. 21 Elevated penile levels of RhoA protein observed in our immunoblot studies and improvement in erectile response seen after Rho-kinase inhibition in SHR group underscore the role of RhoA/Rho-kinase pathway in hypertension-related male ED.
Besides this imbalance in cavernosal tone, hypertension-related alterations in penile trabecular structure may play a significant role in the observed decrement in erectile response in SHR species. In an atherosclerotic animal model of vasculogenic erectile dysfunction, Nehra et al 31 had demonstrated a correlation between erectile tissue structural quality and erectile tissue mechanical property as well as expandability. Wespes 32 has shown that smooth muscular/connective tissue changes could lead to corporeal veno-occlusive dysfunction. These observations collectively indicate that regardless of the amount of penile smooth muscle relaxation, venous occlusion cannot occur in some patients due to a higher content of connective tissue and an inability to occlude the draining vessels. In addition to these structural changes, impairments of the downstream messengers of the NO-cGMP pathway are clearly implicated in hypertension-related smooth muscle dysfunction in the SHR. These mechanisms include downregulation of sGC and the sGC/cGMP/cGKIa pathway, [7] [8] [9] which ultimately could result in reduction in the levels of cGMP, the second messenger that mediates penile smooth muscle relaxation. NO has recently been shown to inhibit RhoA-mediated vasoconstriction and produce an erectile response in rats, possibly through inhibition of RhoA migration into the smooth muscle. 16 Lower bioavailability of NO in SHR species would lead to reduction in RhoA migration to the membrane. The net result would be an increased penile smooth muscle tone, which may be responsible for impaired erectile response seen in the male SHR. Inhibiting the RhoA/Rho-kinase pathway has been shown to cause erection in rats.
12,23 Y-27632 has been shown to inhibit selectively the contractile activity associated with RhoA/Rho-kinase without stimulating vasorelaxation directly. 23 Our results in the present study confirm these observations on the role of the Rhokinase pathway in male erectile function and further suggest that Rho-kinase inhibitors could be of benefit in the treatment of hypertension-related ED.
As hypertension is known to be associated with alterations in the NO-cGMP pathway [7] [8] [9] as well as the Rho-kinase pathway, 15, 30 we extended our studies to examine whether a combination of PDE5 inhibition, which would prevent cGMP degradation, and Rho-kinase antagonism, which would reduce the penile smooth muscle tone, could result in a synergistic improvement of erectile response in SHR species. Our results showed a significant potentiation of EFS-induced erectile response following Rho-kinase and PDE5 inhibition. Recent evidence suggests a significant interplay between the two cyclic nucleotide signaling systems (cAMP and cGMP) and RhoA/Rho-kinase pathways. 33, 34 Crossregulation of intracellular cGMP and cAMP signaling pathways has been demonstrated in cultured human corpus cavernosum smooth muscle cells. 33 Sakai et al 35 reported that accumulation of cAMP in cells inhibited the RhoA activation in tracheal smooth muscle. Using vascular smooth muscle cells, Sauzeau et al 36 demonstrated that cGMP inhibited RhoA-dependent calcium sensitization. This inactivation of the RhoA-Rho-kinase pathway has been proposed to be mediated via cyclic nucleotidedependent protein kinases through phosphorylation of RhoA. 34, 36 These observations taken together suggest that these interactions between cyclic nucleotide signaling systems and the Rho-kinase pathway in penile cavernosal tissue may have important implications in the development of novel combination therapy for ED. Further, our results also suggest that this type of combinations be explored for its potential to improve the erectile response in severe cases of ED, where a modest 41% improvement has been reported with PDE5 inhibition alone. 37 In addition, Rho-kinase inhibition may be explored as an alternate form of therapy for patients to whom Viagra cannot be administered, for example, those on blood pressure medications such as nitrites.
In conclusion, the WKY and SHR strains may serve as ideal animal models for the evaluation of hypertension-associated ED in humans. Rho-kinase inhibition may be a novel therapeutic target in hypertension-related male ED. Combination therapy with PDE5 and Rho-kinase inhibition also merits therapeutic exploration.
